Targeting prostate cancer cell metabolism

Previous activities

Prostate Cancer (PCa) is one of the leading causes of death by cancer in men. In the recent years, it has dramatically increased, most likely due to clinical advances in the early diagnosis and possibly to increasing exposures to environmental pollutants.

The large majority of PCa-related deaths are attributable to advanced, metastatic forms of the disease rather than to localized PCa. During the past six years, we have focused our research on defining molecules able to interfere with the energy metabolism of cancer cells.

We have successfully characterized anti-tumoral actions of several energy disruptors, specifically metformin which targets mitochondrial metabolism and function. A growing body of evidence suggests that mitochondria play a key role in cancer not only in the initiating stages but also in the progression of the disease to the aggressive forms. However, the metabolic modifications underlying PCa metastatic spread are poorly known.

In this context, our program will focus on two main axis:

1) Investigating the metabolic modifications induced by metformin and deciphering the metabolic changes associated with the formation of metastasis in prostate cancer cells.

2) Determining how Environmental Disrupting Chemicals (EDCs) modify cellular and mitochondrial metabolism in relation with PCa progression/aggressiveness.

Team Publications